This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ostrander, J. H. Articles by Lange, C. A. Search for Related Content PubMed PubMed Citation Articles by Ostrander, J. H. Articles by Lange, C. A.

Breast Tumor Kinase (Protein Tyrosine Kinase 6) Regulates Heregulin-Induced Activation of ERK5 and p38 MAP Kinases in Breast Cancer Cells

¹ Departments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota Cancer Center, Minneapolis, Minnesota and ² Department of Pathology, University of Michigan, Ann Arbor, Michigan

Requests for reprints: Carol A. Lange, University of Minnesota Cancer Center, MMC 806, Minneapolis, MN 55455. Phone: 612-626-0621; Fax: 612-626-4915; E-mail: lange047{at}umn.edu.

Total tyrosine kinase activity is often elevated in both cytosolic and membrane fractions of malignant breast tissue and correlates with a decrease in disease-free survival. Breast tumor kinase (Brk; protein tyrosine kinase 6) is a soluble tyrosine kinase that was cloned from a metastatic breast tumor and found to be overexpressed in a majority of breast tumors. Herein, we show that Brk is overexpressed in 86% of invasive ductal breast tumors and coexpressed with ErbB family members in breast cancer cell lines. Additionally, the ErbB ligand, heregulin, activates Brk kinase activity. Knockdown of Brk by stable expression of short hairpin RNA (shRNA) in T47D breast cancer cells decreases proliferation and blocks epidermal growth factor (EGF)- and heregulin-induced activation of Rac GTPase, extracellular signal-regulated kinase (ERK) 5, and p38 mitogen-activated protein kinase (MAPK) but not Akt, ERK1/2, or c-Jun NH₂-terminal kinase. Furthermore, EGF- and heregulin-induced cyclin D1 expression is dependent on p38 signaling and inhibited by Brk shRNA knockdown. The myocyte enhancer factor 2 transcription factor target of p38 MAPK and ERK5 signaling is also sensitive to altered Brk expression. Finally, heregulin-induced migration of T47D cells requires p38 MAPK activity and is blocked by Brk knockdown. These results place Brk in a novel signaling pathway downstream of ErbB receptors and upstream of Rac, p38 MAPK, and ERK5 and establish the ErbB-Brk-Rac-p38 MAPK pathway as a critical mediator of breast cancer cell migration. [Cancer Res 2007;67(9):4199–209]

This article has been cited by other articles:

				A. J. Harvey, C. J. Pennington, S. Porter, R. S. Burmi, D. R. Edwards, W. Court, S. A. Eccles, and M. R. Crompton Brk Protects Breast Cancer Cells from Autophagic Cell Death Induced by Loss of Anchorage Am. J. Pathol., September 1, 2009; 175(3): 1226 - 1234. [Abstract] [Full Text] [PDF]

				A. R. Daniel and C. A. Lange Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells PNAS, August 25, 2009; 106(34): 14287 - 14292. [Abstract] [Full Text] [PDF]

				C.-H. Shen, H.-Y. Chen, M.-S. Lin, F.-Y. Li, C.-C. Chang, M.-L. Kuo, J. Settleman, and R.-H. Chen Breast Tumor Kinase Phosphorylates p190RhoGAP to Regulate Rho and Ras and Promote Breast Carcinoma Growth, Migration, and Invasion Cancer Res., October 1, 2008; 68(19): 7779 - 7787. [Abstract] [Full Text] [PDF]

				B. Xiang, K. Chatti, H. Qiu, B. Lakshmi, A. Krasnitz, J. Hicks, M. Yu, W. T. Miller, and S. K. Muthuswamy Brk is coamplified with ErbB2 to promote proliferation in breast cancer PNAS, August 26, 2008; 105(34): 12463 - 12468. [Abstract] [Full Text] [PDF]